Annexon Inc
NASDAQ:ANNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Annexon Inc
Cash Equivalents
Annexon Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Annexon Inc
NASDAQ:ANNX
|
Cash Equivalents
$160m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$5.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$10.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$18.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
Annexon Inc
Glance View
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 61 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Its pipeline includes three clinical-stage assets across three therapeutic franchises: Autoimmune, Neurodegeneration and Ophthalmology. Its lead candidate, ANX005, is a monoclonal antibody formulated for intravenous administration for several autoimmune indications. ANX005 is being evaluated in a Phase II/III clinical trial for the treatment of patients with Guillain-Barre Syndrome and a Phase II trial in patients with warm autoimmune hemolytic anemia. The company ANX009 clinical candidate is a subcutaneous formulation of an antigen-binding fragment, which is evaluates in a Phase I trial. The company is also developing ANX005, which is in Phase II trials in Huntington’s disease and amyotrophic lateral sclerosis. The firm's ANX007 program is a Fab formulated.
See Also
What is Annexon Inc's Cash Equivalents?
Cash Equivalents
160m
USD
Based on the financial report for Dec 31, 2025, Annexon Inc's Cash Equivalents amounts to 160m USD.
What is Annexon Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-10%
Over the last year, the Cash Equivalents growth was 242%. The average annual Cash Equivalents growth rates for Annexon Inc have been 5% over the past three years , -10% over the past five years .
